Payment overview · 2025
General Payments
$23.61
1 reported records · 1 companies
Healthcare provider profile · identity verified
Ramon E. Negron Rivera, M.D.
Allopathic & Osteopathic Physicians|General Practice · VILLALBA, PR · NPI 1285615021
Verified facts
What the public records show
CMS Open Payments records show Ramon E. Negron Rivera, M.D. received $23.61 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.61 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.61 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 1425 | 294 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1408 | 300 |
| Gabapentin | Gabapentin | 868 | 170 |
| Lisinopril | Lisinopril | 798 | 151 |
| Metoprolol Succinate | Metoprolol Succinate | 756 | 128 |
| Metformin Hcl | Metformin Hcl | 616 | 125 |
| Alendronate Sodium | Alendronate Sodium | 604 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 539 | 96 |
| Clonazepam | Clonazepam | 535 | 92 |
| Synthroid | Levothyroxine Sodium | 531 | 93 |
| Irbesartan | Irbesartan | 479 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 90 |
| Allopurinol | Allopurinol | 405 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 73 |
| Carvedilol | Carvedilol | 351 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 312 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 300 | 159 |
| Montelukast Sodium | Montelukast Sodium | 298 | 69 |
| Meloxicam | Meloxicam | 294 | 150 |
| Furosemide | Furosemide | 280 | 55 |
| Simvastatin | Simvastatin | 268 | 53 |
| Glimepiride | Glimepiride | 266 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 236 | 37 |
| Temazepam | Temazepam | 234 | 40 |
| Candesartan Cilexetil | Candesartan Cilexetil | 223 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 43 |
| Glipizide Er | Glipizide | 217 | 43 |
| Donepezil Hcl | Donepezil Hcl | 190 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 172 | 24 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 167 | 31 |
| Fenofibrate | Fenofibrate | 165 | 36 |
| Spironolactone | Spironolactone | 154 | 26 |
| Prednisone | Prednisone | 152 | 104 |
| Sucralfate | Sucralfate | 151 | 39 |
| Ibandronate Sodium | Ibandronate Sodium | 150 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 26 |
| Fenofibrate | Fenofibrate,micronized | 139 | 33 |
| Finasteride | Finasteride | 132 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 131 | 26 |
| Baclofen | Baclofen | 129 | 76 |
| Risperidone | Risperidone | 129 | 28 |
| Omeprazole | Omeprazole | 126 | 40 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 125 | 22 |
| Humulin N | Insulin Nph Human Isophane | 125 | 20 |
| Lorazepam | Lorazepam | 119 | 16 |
| Sertraline Hcl | Sertraline Hcl | 119 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 20 |
| Cilostazol | Cilostazol | 116 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 34 |
| Metformin Hcl Er | Metformin Hcl | 109 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 16 |
| Buspirone Hcl | Buspirone Hcl | 103 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 100 | 21 |
| Latanoprost | Latanoprost | 98 | 22 |
| Farxiga | Dapagliflozin Propanediol | 97 | 21 |
| Alprazolam | Alprazolam | 94 | 13 |
| Trazodone Hcl | Trazodone Hcl | 94 | 20 |
| Chlorthalidone | Chlorthalidone | 93 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 90 | 16 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 89 | 16 |
| Ramipril | Ramipril | 85 | 19 |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 83 | 21 |
| Eliquis | Apixaban | 77 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 55 |
| Memantine Hcl | Memantine Hcl | 74 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 16 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 68 | 15 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 67 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 60 |
| Tramadol Hcl | Tramadol Hcl | 62 | 11 |
| Pentoxifylline | Pentoxifylline | 61 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 13 |
| Dexamethasone | Dexamethasone | 58 | 44 |
| Levetiracetam | Levetiracetam | 58 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | suppressed |
| Telmisartan | Telmisartan | 57 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 56 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | suppressed |
| Tradjenta | Linagliptin | 55 | 11 |
| Cefadroxil | Cefadroxil | 54 | 51 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | 15 |
| Ciclopirox | Ciclopirox | 51 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 11 |
| Etodolac | Etodolac | 47 | 29 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 46 | 43 |
| Diclofenac Potassium | Diclofenac Potassium | 45 | 30 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 41 |
| Losartan Potassium | Losartan Potassium | 44 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 12 |
| Glipizide | Glipizide | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 38 |
| Theophylline Er | Theophylline Anhydrous | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 16 |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 37 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 23 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 35 | 18 |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nabumetone | Nabumetone | 32 | 16 |
| Easy Touch | Syringe-Needle,insulin,0.5 Ml | 31 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 31 | 27 |
| Diclofenac Sodium Er | Diclofenac Sodium | 29 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Enulose | Lactulose | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Estazolam | Estazolam | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 16 |
| Colchicine | Colchicine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Levoxyl | Levothyroxine Sodium | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | 16 |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Glipizide Xl | Glipizide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | 11 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.61 · 1 records | PFIZER INC. | PAXLOVID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error